Evaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder

Inclusion criteria: • willing to provide written informed consent * men over 50 years with lower urinary tract symptoms and overactive bladder and benign prostatic hyperplasia * persistence of overactive bladder despite 4 weeks of silodosin treatment * symptoms of overactive bladder (urinary frequency and urgency with or without urinary incontinence) for ≥3 months prior to visit 1. * willing and able to complete the 3-day voiding diary and questionnaires * International Prostate Symptom Score (IPSS) score ≥8. * experience an average of 8 or more micturition's per day over the 3-day diary period. * experience an average of 2 episodes of urgency per day (grade 3 or 4) over the 3-diary period Exclusion criteria: * post-void residual volume (PVR) \>200 mL * evidence of Urinary Tract Infection and haematuria * use anticholinergics, beta 3 mimetics within 4 weeks prior to Visit 1 and during the study * oncological diseases of the lower urinary tract and prostate * neurogenic bladder * urethral strictures and bladder neck stenosis * urolithiasis * diabetes mellitus * previous surgery of lower urinary tract * stress urinary incontinence * intermittent catheterisation * chronic urinary tract infection * previous botox treatment in the last 12 months * chronic electrostimulation treatment of OAB in the last 12 months * patient began or has changed a bladder training program or pelvic floor exercises less than 90 days before 1 visit * cognitive deficits and dementia * man has participated in an interventional trial within 30 days prior to Visit 1 * total daily urine production over 2500 mL according to voiding diary